U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06826859) titled 'Daily Aspirin Vs Split Dosing in High-risk Pregnancies (DASH)' on Jan. 28.
Brief Summary: Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin pharmacology and the relationship of aspirin response and pregnancy outcome, along with a lack of consensus on aspirin dosing has limited the effective use of this intervention. The investigators aim to apply principles of clinical pharmacology to dete...